Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)


Por: Sepulveda-Sanchez J, Gil-Gil M, Alonso-Garcia M, Salgado M, Vicente E, Barroso C, Sanchez A, Duran G, de las Penas R, Munoz-Langa J, Velasco G, Hernandez-Lain A, Hilario A, Martin M, Benavides M, Oleaga L, Montenegro D, Ruano Y, Sanchez-Gomez P, Martin-Soberon M, Morales-Llombart R, Pachon V, Pineda E

Publicada: 1 oct 2020 Ahead of Print: 1 oct 2020
Resumen:
Background The cell cycle checkpoint G1/S, dependent on cyclin-dependent kinase (CDK) 4 amplification/overexpression and retinoblastoma phosphorylation, is altered in most anaplastic oligodendrogliomas (AOs). Objective We aimed to evaluate the efficacy of palbociclib, an oral inhibitor of CDK4/6 with proven efficacy in breast cancer, in patients with AO. The primary endpoint was progression-free survival at 6 months. Patients and Methods We conducted a multicenter, open-label, phase II trial evaluating the efficacy and safety of palbociclib in patients with AO who progressed on radiotherapy and chemotherapy with histologically and molecularly confirmed grade 3 oligodendroglioma and conserved retinoblastoma protein (pRb) expression by immunohistochemistry. Patients were treated with palbociclib (125 mg/day) for 3/1 weeks on/off. Results Overall, 34 patients were enrolled across 10 hospitals in the Spanish Group of Neuro-Oncology (GEINO) study. The study was stopped early owing to the lack of efficacy, with 74% of evaluable patients progressing within 6 months, which was insufficient to consider palbociclib as an active drug in this population. Within the median follow-up of 12 months, the median progression-free survival was 2.8 months [95% confidence interval (CI) 2.6-3.1] and the median overall survival was 32.1 months (95% CI 5.1-59.2). There were no partial or complete responses; only 13 patients (38%) achieved stable disease as the best response. Palbociclib was well tolerated, with neutropenia (grade 3 or higher: 58.8%) and thrombocytopenia (grade 3 or higher: 14.7%) as the most common adverse events (AEs). Both AEs had no significant impact. Conclusion Despite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.

Filiaciones:
Sepulveda-Sanchez J:
 Hosp Univ 12 Octubre, Med Oncol Dept, Avda Andalucia S-N, Madrid 28041, Spain

Gil-Gil M:
 Inst Catala Oncol LHospitalet, Med Oncol Dept, Barcelona, Spain

Alonso-Garcia M:
 Hosp Univ Virgen del Rocio, Med Oncol Dept, Seville, Spain

Salgado M:
 Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain

Vicente E:
 Hosp Univ Insular Gran Canaria, Med Oncol Dept, Las Palmas Gran Canaria, Spain

Barroso C:
 Inst Catala Oncol LHospitalet, Med Oncol Dept, Barcelona, Spain

Sanchez A:
 Hosp Univ Leon, Med Oncol Dept, Leon, Spain

Duran G:
 Hosp Univ Reg & Virgen de la Victoria, Unidad Gest Clin Interctr Oncol Med, IBIMA, Malaga, Spain

de las Penas R:
 Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon de La Plana, Spain

Munoz-Langa J:
 Hosp Univ & Policlin La Fe, Med Oncol Dept, Valencia, Spain

Velasco G:
 Univ Complutense Madrid, Chem Sci Fac, Madrid, Spain

Hernandez-Lain A:
 Hosp Univ 12 Octubre, Inst Invest Biomed I 12, Dept Pathol Neuropathol, Madrid, Spain

Hilario A:
 Universitary Hosp 12 Octubre, Radiol Dept, Madrid, Spain

Martin M:
 Hosp Univ Salamanca, Med Oncol Dept, Salamanca, Spain

Benavides M:
 Hosp Univ Reg & Virgen de la Victoria, Unidad Gest Clin Interctr Oncol Med, IBIMA, Malaga, Spain

Oleaga L:
 Hosp Clin Barcelona, Radiol Dept, Barcelona, Spain

Montenegro D:
 Hosp Univ 12 Octubre, Neurooncol Mol Biol Dept, Madrid, Spain

Ruano Y:
 Hosp Univ 12 Octubre Res Inst, Mol Pathol Unit, Madrid, Spain

Sanchez-Gomez P:
 Inst Salud Carlos III UFIEC, Neurooncol Unit, Madrid, Spain

Martin-Soberon M:
 Hosp Univ 12 Octubre, Med Oncol Dept, Avda Andalucia S-N, Madrid 28041, Spain

Morales-Llombart R:
 MFAR Clin Res, Barcelona, Spain

Pachon V:
 Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain

Pineda E:
 August Pi i Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

 Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
ISSN: 17762596





Targeted Oncology
Editorial
Springer Verlag, VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS, Francia
Tipo de documento: Article
Volumen: 15 Número: 5
Páginas: 613-622
WOS Id: 000575697800001
ID de PubMed: 33025213

MÉTRICAS